Alzheimer's disease | pharmaphorum

Wednesday 20 May 2026

Alzheimer's disease

News

Alzheimer's biotech Korsana to go public via reverse merger

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

Anavex sinks after pulling Alzheimer's filing in EU

Anavex sinks after pulling Alzheimer's filing in EU

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.

News

Appeal finds NICE must reconsider Alzheimer's drugs

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Finger-prick blood test

Could Alzheimer's be predicted with a finger-prick test?

An international trial has started to see if a simple finger-prick blood test could predict Alzheimer's before symptoms start.

News

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

News

Tangled string

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.